Akero Therapeutics Inc (AKRO)

Sector:
HEALTH CARE
Industry:
BIOTECHNOLOGY & LIFE SCIENCES
SIC:
PHARMACEUTICAL PREPARATIONS
CEO:
Andrew Cheng
Employees:
40
170 HARBOR WAY, SOUTH SAN FRANCISCO, CA 94080
650-487-6488

Akero Therapeutics, Inc. engages in the development of medicines designed to restore metabolic balance and improve overall health. The company's lead product candidate is efruxifermin (EFX), an analog of fibroblast growth factor 21, which protects against cellular stress and regulates metaboli® of lipids, carbohydrates, and proteins.

Data derived from most recent annual or quarterly report
Market Cap 1.863 Billion Shares Outstanding46.763 Million Avg 30-day Volume 666.099 Thousand
P/E Ratio0.0 Dividend Yield0.0 EPS-0.92
Price to Revenue0.0 Debt to Equity0.0 EBITDA-99.779 Million
Price to Book Value4.3558 Operating Margin0.0 Enterprise Value548.341 Million
Current Ratio7.704 EPS Growth-0.147 Quick Ratio7.492
1 Yr BETA -0.2422 52-week High/Low 54.88 / 7.52 Profit Margin0.0
Operating Cash Flow Growth-12.5374 Altman Z-Score13.8258 Free Cash Flow to Firm -61.146 Million
Earnings Report2023-05-05
View SEC Filings from AKRO instead.

View recent insider trading info

Akero Therapeutics Inc YCharts
Yahoo! Finance finviz
SEC Web Site SEC DEF 14A Filings

Funds Holding AKRO (via 13F filings)

Refresh Download CSV Download Excel (.xlsx) Download TSV
Filter by:
Click for Additional Filters
to
to
to
Refresh
*Shares are split adjusted
*Please note that if a filer hasn't submitted a 13F filing for a quarter then the filer's shares will be listed as "Sold All"

Mutual Funds Holding AKRO

Download CSV

Active Schedule 13D and 13G filings

Please sign in first

Recent Filings

Financial Reporting

Ownership

  • 4: filed on 2023-03-14 by WHITE WILLIAM RICHARD
  • 4: filed on 2023-03-14 by YALE CATRIONA
  • 4: filed on 2023-03-14 by YOUNG JONATHAN
  • 4: filed on 2023-03-14 by CHENG ANDREW
  • 4: filed on 2023-03-03 by CHENG ANDREW
  • 4: filed on 2023-02-03 by CHENG ANDREW
  • 4: filed on 2023-01-18 by YALE CATRIONA
  • 4: filed on 2023-01-11 by LAMY PATRICK
  • 3: filed on 2023-01-11 by LAMY PATRICK
  • 4: filed on 2023-01-05 by CHENG ANDREW

    • Events (8k)

  • 8-K: filed on 2023-03-17:
    Item 1.01: Entry into a Material Definitive Agreement
    Item 1.02: Termination of a Material Definitive Agreement
    Item 9.01: Financial Statements and Exhibits
  • 8-K: filed on 2023-03-17:
    Item 2.02: Results of Operations and Financial Condition
    Item 9.01: Financial Statements and Exhibits
  • 8-K: filed on 2022-11-04:
    Item 2.02: Results of Operations and Financial Condition
    Item 9.01: Financial Statements and Exhibits
  • 8-K: filed on 2022-09-16:
    Item 1.01: Entry into a Material Definitive Agreement
    Item 9.01: Financial Statements and Exhibits
  • 8-K: filed on 2022-09-13:
    Item 7.01: Regulation FD Disclosure
    Item 8.01: Other Events
    Item 9.01: Financial Statements and Exhibits
  • 8-K: filed on 2022-06-16:
    Item 1.01: Entry into a Material Definitive Agreement
    Item 2.03: Creation of a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement of a Registrant
    Item 7.01: Regulation FD Disclosure
    Item 9.01: Financial Statements and Exhibits
  • 8-K: filed on 2022-06-08:
    Item 7.01: Regulation FD Disclosure
    Item 9.01: Financial Statements and Exhibits
  • 8-K: filed on 2022-05-06:
    Item 2.02: Results of Operations and Financial Condition
    Item 9.01: Financial Statements and Exhibits
  • 8-K: filed on 2022-02-25:
    Item 2.02: Results of Operations and Financial Condition
    Item 9.01: Financial Statements and Exhibits
  • 8-K: filed on 2021-12-10:
    Item 5.02: Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers

    • Proposed Sales (Form 144)

    Proxy

    Prospectus

    All

    Open Market Buys/Sells Last 60 Days

    Open Market Buys (P)

    none

    Open Market Sells (S)

    50 Thousand total shares from 6 transactions

    Exercise Derivative Conversion (M)

    50 Thousand total shares from 2 transactions

    Current/Former Insiders

    Insider Name Type Last Reported Shares Held Last Reported Date Filings in past year

    CHENG ANDREW PRESIDENT & CEO

    • Officer
    • Director
    		 369,293 2023-03-10 11

    WHITE WILLIAM RICHARD CHIEF FINANCIAL OFFICER

    • Officer
    		 22,983 2023-03-10 7

    YALE CATRIONA CHIEF DEVELOPMENT OFFICER

    • Officer
    		 80,567 2023-03-10 8

    ROLPH TIMOTHY CHIEF SCIENTIFIC OFFICER

    • Officer
    		 189,929 2023-03-10 11

    YOUNG JONATHAN CHIEF OPERATING OFFICER

    • Officer
    		 204,277 2023-03-10 7

    LAMY PATRICK SEE REMARKS

    • Officer
    		 0 2023-01-10 2

    SKORPIOS TRUST

    BLUE HORIZON ENTERPRISE LTD

    EZBON INTERNATIONAL LTD

    MONTRAGO TRUSTEES LTD

    • FORMER 10% OWNERFORMER 10% OWNERFORMER 10% OWNERFORMER 10% OWNER
    		 3,271,829 2022-12-01 1

    HARRISON SETH LORING

    • Director
    		 284,364 2022-11-30 4

    IWICKI MARK T

    • Director
    		 15,000 2022-06-02 1

    HENDERSON JANE

    • Director
    		 15,000 2022-06-02 1

    GRAHAM G. WALMSLEY

    • Director
    		 15,000 2022-06-02 1

    HEYMAN TOMAS J.

    • Director
    		 15,000 2022-06-02 1

    XU YUAN

    • Director
    		 15,000 2022-06-02 1

    JUDY CHOU

    • Director
    		 15,000 2022-06-02 1

    ATP LIFE SCIENCE VENTURES, L.P.

    ATP III GP, LTD.

    • 10% Owner
    		 No longer subject to file 2021-06-28 0

    BITTERMAN KEVIN

    • Director
    		 2,232,251 2021-06-01 0

    VENBIO GLOBAL STRATEGIC FUND II L.P.

    VENBIO GLOBAL STRATEGIC GP II, L.P.

    VENBIO GLOBAL STRATEGIC GP II, LTD.

    ADELMAN ROBERT J

    GOODMAN COREY S

    • 10% Owner
    		 3,033,552 2020-07-01 0

    ATLAS VENTURE OPPORTUNITY FUND I, L.P.

    • 10% Owner
    		 404,079 2020-02-07 0

    VERSANT VENTURE CAPITAL VI, L.P.

    VERSANT VENTURES VI GP, L.P.

    VERSANT VENTURES VI GP-GP, LLC

    • 10% Owner
    		 3,092,698 2020-01-16 0

    ATLAS VENTURE FUND XI, L.P.

    • 10% Owner
    		 2,706,412 2019-12-31 0

    VERSANT VENTURE CAPITAL VI, L.P.

    • 10% Owner
    		 3,656,585 2019-12-27 0

    ATLAS VENTURE FUND XI, L.P.

    ATLAS VENTURE OPPORTUNITY FUND I, L.P.

    • 10% Owner
    		 3,403,884 2019-12-17 0

    REDMILE GROUP, LLC

    GREEN JEREMY

    • 10% Owner
    		 No longer subject to file 2019-06-24 0

    ATLAS VENTURE FUND XI, L.P.

    ATLAS VENTURE ASSOCIATES XI, LLC

    ATLAS VENTURE ASSOCIATES XI, L.P.

    ATLAS VENTURE ASSOCIATES OPPORTUNITY I, L.P.

    ATLAS VENTURE ASSOCIATES OPPORTUNITY I, LLC

    ATLAS VENTURE OPPORTUNITY FUND I, L.P.

    • 10% Owner
    		 3,974,858 2019-06-24 0

    ROYSTON AARON

    • Director
    		 3,954,858 2019-06-24 0

    APPLE TREE PARTNERS IV, L.P.

    ATP III GP, LTD.

    HARRISON SETH LORING

    • Director
    • 10% Owner
    		 0 2019-06-19 0

    Insider Transactions Last 60 Days

    Reporting Owners Filing Date Trans Date Trans Code Shares Share Price Acquired
    Disposed    		 Shares Owned after D/I 10b5 Perf 1d* Perf 5d* Perf 1m* Max Gain Max Gain Days Max Loss Max Loss Days

    YALE CATRIONA - Officer CHIEF DEVELOPMENT OFFICER

    		2023-03-14 16:20:52 -0400 2023-03-10 F 701 $43.46 d 80,567 direct -1.9008 -6.3688 0.0 1 -7.998 5

    YOUNG JONATHAN - Officer CHIEF OPERATING OFFICER

    		2023-03-14 16:19:46 -0400 2023-03-10 F 634 $43.47 d 184,277 direct -1.9008 -6.3688 0.0 1 -7.998 5

    CHENG ANDREW - Director - Officer PRESIDENT & CEO

    		2023-03-14 16:18:06 -0400 2023-03-10 F 1,706 $43.47 d 369,293 direct -1.9008 -6.3688 0.0 1 -7.998 5

    ROLPH TIMOTHY - Officer CHIEF SCIENTIFIC OFFICER

    		2023-03-14 16:19:37 -0400 2023-03-10 F 603 $43.47 d 189,929 direct -1.9008 -6.3688 0.0 1 -7.998 5

    WHITE WILLIAM RICHARD - Officer CHIEF FINANCIAL OFFICER

    		2023-03-14 16:25:14 -0400 2023-03-10 F 641 $43.47 d 22,983 direct -1.9008 -6.3688 0.0 1 -7.998 5

    CHENG ANDREW - Director - Officer PRESIDENT & CEO

    		2023-03-03 16:21:36 -0500 2023-03-01 S 2,265 $45.54 d 393,734 direct yes -0.1267 -11.402 0.0 1 -12.69 5

    CHENG ANDREW - Director - Officer PRESIDENT & CEO

    		2023-03-03 16:21:36 -0500 2023-03-01 S 6,700 $47.17 d 370,999 direct yes -0.1267 -11.402 0.0 1 -12.69 5

    CHENG ANDREW - Director - Officer PRESIDENT & CEO

    		2023-03-03 16:21:36 -0500 2023-03-01 S 16,035 $46.60 d 377,699 direct yes -0.1267 -11.402 0.0 1 -12.69 5

    CHENG ANDREW - Director - Officer PRESIDENT & CEO

    		2023-03-03 16:21:36 -0500 2023-03-01 M 25,000 $0.62 a 395,999 direct yes -0.1267 -11.402 0.0 1 -12.69 5

    CHENG ANDREW - Director - Officer PRESIDENT & CEO

    		2023-03-03 16:21:36 -0500 2023-03-01 M 25,000 d 135,868 direct yes

    CHENG ANDREW - Director - Officer PRESIDENT & CEO

    		2023-02-03 17:25:28 -0500 2023-02-01 S 2,000 $50.14 d 370,999 direct yes -3.0128 -4.0812 -20.3632 1.6667 19 -20.3632 31

    CHENG ANDREW - Director - Officer PRESIDENT & CEO

    		2023-02-03 17:25:28 -0500 2023-02-01 S 8,155 $49.67 d 372,999 direct yes -3.0128 -4.0812 -20.3632 1.6667 19 -20.3632 31

    CHENG ANDREW - Director - Officer PRESIDENT & CEO

    		2023-02-03 17:25:28 -0500 2023-02-01 S 14,845 $48.57 d 381,154 direct yes -3.0128 -4.0812 -20.3632 1.6667 19 -20.3632 31

    CHENG ANDREW - Director - Officer PRESIDENT & CEO

    		2023-02-03 17:25:28 -0500 2023-02-01 M 25,000 $0.62 a 395,999 direct yes -3.0128 -4.0812 -20.3632 1.6667 19 -20.3632 31

    CHENG ANDREW - Director - Officer PRESIDENT & CEO

    		2023-02-03 17:25:28 -0500 2023-02-01 M 25,000 d 160,868 direct yes

    * -

    Transaction Code Definitions
    Code Definition
    A Grant, award or other acquisition pursuant to Rule 16b-3(d)
    C Conversion of derivative security
    D Disposition to the issuer of issuer equity securities pursuant to Rule 16b-3(e)
    E Expiration of short derivative position
    F Payment of exercise price or tax liability by delivering or withholding securities incident to the receipt, exercise or vesting of a security issued in accordance with Rule 16b-3
    G Bona fide gift
    H Expiration (or cancellation) of long derivative position with value received
    I Discretionary transaction in accordance with Rule 16b-3(f) resulting in acquisition or disposition of issuer securities
    J Other acquisition or disposition
    L Small acquisition under Rule 16a-6
    M Exercise or conversion of derivative security exempted pursuant to Rule 16b-3
    O Exercise of out-of-the-money derivative security
    P Open market or private purchase of non-derivative or derivative security
    S Open market or private sale of non-derivative or derivative security
    U Disposition pursuant to a tender of shares in a change of control transaction
    W Acquisition or disposition by will or the laws of descent and distribution
    X Exercise of in-the-money or at-the-money derivative security
    Z Deposit into or withdrawal from voting trust

    IBR Securities Loan Availability

    Updated throughout the day, this shows the number of shares available to borrow. Data provided by Interactive Brokers

    Security Date/Time Rebate Rate Fee Rate Shares Available
    AKERO THERAPEUTICS INC AKRO 2023-03-24 15:45:03 UTC 4.5317 0.2883 550000
    AKERO THERAPEUTICS INC AKRO 2023-03-24 15:15:03 UTC 4.5317 0.2883 550000
    AKERO THERAPEUTICS INC AKRO 2023-03-24 14:45:03 UTC 4.5317 0.2883 550000
    AKERO THERAPEUTICS INC AKRO 2023-03-24 14:15:03 UTC 4.5317 0.2883 550000
    AKERO THERAPEUTICS INC AKRO 2023-03-24 13:45:03 UTC 4.1324 0.4376 550000
    AKERO THERAPEUTICS INC AKRO 2023-03-24 13:15:04 UTC 4.1324 0.4376 550000
    AKERO THERAPEUTICS INC AKRO 2023-03-24 12:45:03 UTC 4.1324 0.4376 550000
    AKERO THERAPEUTICS INC AKRO 2023-03-23 22:15:04 UTC 4.1324 0.4376 550000
    AKERO THERAPEUTICS INC AKRO 2023-03-23 21:45:04 UTC 4.1324 0.4376 550000
    AKERO THERAPEUTICS INC AKRO 2023-03-23 21:15:04 UTC 4.1324 0.4376 550000
    AKERO THERAPEUTICS INC AKRO 2023-03-23 20:45:03 UTC 4.32 0.25 550000
    AKERO THERAPEUTICS INC AKRO 2023-03-23 20:15:03 UTC 4.32 0.25 550000
    AKERO THERAPEUTICS INC AKRO 2023-03-23 19:45:03 UTC 4.32 0.25 550000
    AKERO THERAPEUTICS INC AKRO 2023-03-23 19:15:03 UTC 4.32 0.25 650000
    AKERO THERAPEUTICS INC AKRO 2023-03-23 18:45:04 UTC 4.32 0.25 650000
    AKERO THERAPEUTICS INC AKRO 2023-03-23 18:15:03 UTC 4.32 0.25 550000
    AKERO THERAPEUTICS INC AKRO 2023-03-23 17:45:03 UTC 4.32 0.25 550000
    AKERO THERAPEUTICS INC AKRO 2023-03-23 17:15:03 UTC 4.32 0.25 650000
    AKERO THERAPEUTICS INC AKRO 2023-03-23 16:45:04 UTC 4.32 0.25 650000
    AKERO THERAPEUTICS INC AKRO 2023-03-23 16:15:03 UTC 4.32 0.25 600000

    Current Active Short Positions

    Holder Issuer Net Short Position Position Date Origin
    FundVantage Trust- Gotham Index Plus All-Cap Fund AKRO -3.0 shares, $-63.6 2020-03-31 N-PORT
    RUSSELL INVESTMENT CO- U.S. Small Cap Equity Fund AKRO -3127.0 shares, $-132147.02 2022-10-31 N-PORT
    INVESTMENT MANAGERS SERIES TRUST- 361 Domestic Long/Short Equity Fund AKRO -323.0 shares, $-13649.98 2022-10-31 N-PORT
    RUSSELL INVESTMENT FUNDS- U.S. Small Cap Equity Fund AKRO -190.0 shares, $-10412.0 2022-12-31 N-PORT

    Congressional Transactions Past 6-Months

    To see all congressional transactions (since 2022) for this stock, please use the congressional transaction search page***
    Congress Person Party Chamber Filing Filing Date Transaction Date Security Type Owner Transaction Amount
    Hon. Christopher L. Jacobs republican House Filing 2022-12-07 2022-11-08 P $1,001-$15,000

    Elevate your investments